REFERENCES
- Scheld WM. Managing fluoroquinolone class efficacy. Emerg Inf Dis 2003; 9: 1–9.
- Romanelli G, Cravarezza P, Pozzi A, et al. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. J Chemother 2002; 14: 609–17.
- Mylotte JM, Tayara A, Goodnough S. Epidemiology of bloodstream infection in nursing home residents: evaluation in a large cohort from multiple homes. Clin Infect Dis 2002; 35: 1484–90.
- Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis 2002; 35: 1505–11.
- Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 2003; 51: 691–6.
- Simonsen GS, Smabrekke L, Monnet DL, et al. Prevalence of resistance to ampicillin, gentamicin and van-comycin in Enterococcus faecalis and Enterococcus faecium isolates from clinical specimens and use of antimicrobials in five Nordic hospitals. J Antimicrob Chemother 2003; 51: 323–31.
- Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. Relationship between beta-lac-tamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumanii. J Antimicrob Chemother 2002; 51: 565–74.
- Ban-Hock T, Ai-Ling. Community-acquired bacteremia with ESBL-producing Escherichia coll. Int J Infect Dis 2002; 6: 318–9.
- Alobwede I, M'Zali FH, Livermore DM, Heritage J, Todd N, Hawkey PM. CTX-M extended-spectrum beta-lacta-mase arrives in the UK. J Antimicrob Chemother 2003; 51: 470–1.
- Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother 2003; 51: 347–52.
- Brenwald NP, Jevons G, Andrews JM, Xiong JH, Hawkey PM, Wise R. An outbreak of a CTX-M-type beta-lac-tamase-producing Klebsiella pneumoniae: the importance of using cefpodoxime to detect extended-spectrum beta-lacta-mases. J Antimicrob Chemother 2003; 51: 195–6.